You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
-
Leveraging platelet signal transduction for personalized antiplatelet therapy
SBC: PlateletDiagnostics, LLC Topic: NHLBIProject Summary/Abstract Platelet-mediated thrombosis causes both coronary arterial disease (CAD) and stroke, the first and fifth most common causes of mortality in the US. Antiplatelet agents, typically aspirin and/or clopidogrel, significantly improve survival in patients with CAD or stroke and have remained a mainstay of treatment for more than two decades. Yet despite the consensus that platel ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Development of protease activity-based detector substrates for diagnosing Candida infections
SBC: BioSynesis, Inc. Topic: NIAIDProject Summary/Abstract Members of the Candida genus of fungi form part of the normal human microbiota but are also opportunistic pathogens capable of causing serious mucosal and systemic infections. Candida cells grow and divide in suspension (planktonic) cultures, but they also form resilient and drug resistant biofilms – organized, tightly- packed communities of cells that attach to surfaces ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Development of novel, targeted small molecule inhibitors of DNA repair in high unmet need tumors-TNBC
SBC: DNATWO, Inc. Topic: NCIDNATWO, Inc. was founded out of Caltech to develop small molecule drugs targeting a new cancer target, DNA2, to treat triple-negative breast cancer (TNBC). We have spent decades unraveling the role of the DNA2 ATP-motor driven nuclease activity in relieving replication stress at the replication fork and carrying out repair at forks collapsed to double strand breaks (DSBs). Our scientific premise i ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
An automated system to differentiate Kawasaki disease from febrile illness with real life clinical datasets in New York City
SBC: HBI SOLUTIONS INC. Topic: 100ABSTRACT – Kawasaki disease (KD) is the most common cause of acquired heart disease in children. Treatment with intravenous immunoglobulin (IVIG) reduces the incidence of coronary aneurysms and risk of long-term cardiovascular complications. IVIG is recommended to be given within 10 days of illness; however only 4.7% receive the correct diagnosis at the first medical visit. Timely and accurately ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Clinical Decision Support System to Optimize Neonatal Nutrition and Growth
SBC: Medical Predictive Science Corporation Topic: NICHDProject Summary/Abstract: Clinical Decision Support System to Optimize Neonatal Nutrition and Growth Nutrition, defined as energy, macronutrients (protein, fat, and carbohydrates), and micronutrients (e.g., electrolytes), is a critical feature of care for preterm infants in the neonatal intensive unit (NICU). Inadequate nutrition is associated with growth and neurodevelopmental impairment, and inc ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Development and Evaluation of an Integrated Biomarker Capture System for Use in Remote Trials
SBC: MOUNTAINPASS TECHNOLOGY LLC Topic: NCATSABSTRACT Remote trials are led and coordinated by a local investigative team, but are based remotely, typically in the participant’s home. Remote trials offer several advantages over traditional in-person trials including: 1) a wider participant pool, 2) reduced regulatory hurdles, and 3) reduced participant burden. Remote trials face one key methodological limitation: the need for biomarker col ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Glycoengineering of CHO cells to express recombinant alpha-1 antitrypsin
SBC: NEUIMMUNE BIOLOGICS, INC. Topic: NHLBIABSTRACTAlpha-1 antitrypsin (A1AT) is well-established as a biotherapeutic used for the treatment of alpha-1 antitrypsin deficiency, and shows promise for treating a variety of other diseases. However, A1AT augmentation therapy carries unnecessary risk since it relies upon the weekly transfusion of plasma-derived product, which presents supply chain and contaminant risks. This could be remedied wi ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Targeting a non-opioid signaling pathway to reverse opioid-induced respiratory depression
SBC: Olfa Thera, Inc. Topic: NIDAProject Summary/AbstractThe opioid epidemic is a growing public health crisis with dramatic increase in overdose deaths caused by potent opioids like fentanyl. Currently, the standard treatment for opioid-induced respiratory depression is naloxone, a µ-opioid receptor antagonist. However, naloxone is less effective against potent synthetic opioids like fentanyl and induces withdrawal in chronic o ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Development of negative allosteric modulators of the mu-opioid receptor for the management of opioid use disorder
SBC: Eleven Therapeutics Corp Topic: NIDAAbstract There is a significant need for new treatments for opioid use disorder (OUD) to manage patients abusing heroin, fentanyl, oxycodone and related drugs. Buprenorphine and methadone are both effective medications for OUD but are agonists with potential for abuse and diversion, and with methadone the risk of respiratory depression and overdose death. Moreover, these compounds are not effectiv ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Injectable Ice Slurry Cooling Technology for Treatment of Postoperative Pain
SBC: Brixton Biosciences, Inc. Topic: NIAMSProject SummaryTotal knee arthroplasty (TKA) is one of the most commonly performed orthopedic surgeries to relieve joint pain in patients with end-stage osteoarthritis or rheumatic arthritis. In the United States, over 700,000 TKA procedures are performed each year. Most patients experience significant pain after TKA. To manage this pain, patients are commonly prescribed opioids, contributing to a ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health